Clinical Trial Update: Patients Completing Core Protocol (CAMN107A2103), Exhibiting Stable Disease (SD), Partial Response (PR) or Complete Response (CR) to Nilotinib in Combination With Imatinib [Phase 1]

View source ↗

Summary

Phase 1 study CAMN107A2103 in gastrointestinal stromal tumors shows patients achieving stable disease, partial response, or complete response when treated with …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastrointestinal Stromal Tumor

Drugs mentioned

• Gleevec (Imatinib)
• Tasigna (nilotinib)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Gastrointestinal Stromal Tumors | Phase 1 | Status: COMPLETED